| 42623-9 |
Coxsackievirus A3 Ab |
Titr |
Ser |
Pt |
SemiQn |
|
|
ACTIVE |
Coxsackievirus A3 Ab [Titer] in Serum |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42623-9 |
|
|
|
|
Both |
|
|
|
0 |
CV A3 Ab Titr Ser |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A3; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Point in time; Random; Serum; SmQn; SR; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 42624-7 |
Gastrin^2M post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Gastrin [Mass/volume] in Serum or Plasma --2 minutes post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHAL |
|
42624-7 |
|
|
|
|
Observation |
|
|
|
0 |
Gastrin 2M p chal SerPl-mCnc |
|
|
|
N |
|
2M p chal; After; CHEMISTRY.CHALLENGE TESTING; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Total gastrins; Zollinger-Ellison syndrome |
2.73 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 42625-4 |
Coxsackievirus A6 Ab |
Titr |
Ser/Plas |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Coxsackievirus A6 Ab [Titer] in Serum |
|
MIN |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42625-4 |
|
|
|
|
Both |
|
|
|
0 |
Deprecated CV A6 Ab Titr SerPl |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CAV; Coxsackie; Coxsackie virus; CV; CV A6; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Microbiology; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Titer; Titered; Titre; Ttr |
2.7 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 42626-2 |
Toxoplasma gondii DNA |
PrThr |
CSF |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Toxoplasma gondii DNA [Presence] in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42626-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
T gondii DNA CSF Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; T gondii; T gondii DNA; TMA; Toxo; Toxoplasmosis; Transcription mediated amplification |
2.63 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42627-0 |
HIV 1 Ab |
PrThr |
CSF |
Pt |
Ord |
IF |
|
ACTIVE |
HIV 1 Ab [Presence] in Cerebral spinal fluid by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42627-0 |
|
IF |
|
|
Both |
|
|
|
0 |
HIV1 Ab CSF Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; AIDS; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; FA; Fluorescent antibody; Fluoresent; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Time Resolved Fluorescence; TRF |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42628-8 |
Cells.CD9+CD41+/Cells |
NFr |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD9+CD41+ cells/cells in Blood |
|
NAM |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CELLMARK |
|
42628-8 |
|
|
|
|
Both |
|
|
|
0 |
CD9+CD41+ Cells NFr Bld |
|
|
|
N |
|
alpha IIb integrin chain; Blood; CD9 Cells; CD9+CD41+ Cells; Cell; CELL MARKERS; Cellularity; DRAP-27; Glycoprotein IIB; GPIIb; MRP-1; Number fraction; p24; Percent; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.79 |
2.16 |
|
|
|
|
|
|
|
% |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 42629-6 |
Glucose^4H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --4 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42629-6 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 4h p Lac PO Ur-mCnc |
|
|
|
N |
|
4h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 4263-0 |
fluPHENAZine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
fluPHENAZine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4263-0 |
|
|
|
|
Observation |
|
|
|
0 |
fluPHENAZine Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Fluphenazine Hydrochloride; Point in time; Prolixin; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 42630-4 |
Cannabinoids |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Cannabinoids [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
Negative |
|
|
|
|
|
DRUG/TOX |
|
42630-4 |
|
|
|
|
Both |
|
|
|
0 |
Cannabinoids Bld Ql |
|
|
|
N |
|
Addiction; Blood; Cannabinoid; Delta-9-tetrahydrocannabinol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Marijuana; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; THC; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42631-2 |
Glucose^5H post dose lactose PO |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Urine --5 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
42631-2 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 5h p Lac PO Ur-mCnc |
|
|
|
N |
|
5h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; LTT; Mass concentration; p dose; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.16 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 42632-0 |
Grade ICD-O-1 |
Prid |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Grade ICD-O-1 Cancer |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
TUMRRGT |
|
42632-0 |
|
|
|
|
|
|
|
|
0 |
Grade ICD-O-1 Cancer |
|
|
|
N |
|
CA; i; Identity or presence; International Classification of Diseases; International Classification of Diseases for Oncology; Misc; Miscellaneous; Nominal; Oncology; Other; Point in time; Random; Spec; To be specified in another part of the message; TUMOR REGISTRY(NAACCR); Unspecified |
2.32 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42633-8 |
Behavior ICD-O-1 |
Prid |
Cancer.XXX |
Pt |
Nom |
|
|
ACTIVE |
Behavior ICD-O-1 Cancer |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
TUMRRGT |
|
42633-8 |
|
|
|
|
|
|
|
|
0 |
Behavior ICD-O-1 Cancer |
|
|
|
N |
|
CA; i; Identity or presence; International Classification of Diseases; International Classification of Diseases for Oncology; Misc; Miscellaneous; Nominal; Oncology; Other; Point in time; Random; Spec; To be specified in another part of the message; TUMOR REGISTRY(NAACCR); Unspecified |
2.32 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42634-6 |
1p & 19q chromosome deletion |
Arb |
Tiss fixed |
Pt |
Ord |
Molgen |
|
ACTIVE |
1p and 19q chromosome deletion [Presence] in Fixed tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.DEL |
|
42634-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
1p+19q Del Ftis Ql |
|
|
|
N |
|
1p & 19q; 1p/19q; 1p+19q; Arbitrary; Chromosom; Chromosomes; d(1p,19q); Del; Del(1p,19q) gene deletion; Deletions; Fixed tissue; Ftis; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.DELETIONS; Oligodendroglioma; Ordinal; PCR; Point in time; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42635-3 |
Chromosome 12p tetrasomy |
Arb |
Tiss fixed |
Pt |
Ord |
Molgen |
|
ACTIVE |
Chromosome 12p tetrasomy [Presence] in Fixed tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
Molecular cytogenetics interpretation and report |
|
|
|
|
|
MOLPATH |
|
42635-3 |
|
Molgen |
|
|
Both |
|
|
|
0 |
Chr 12p tetrasomy Ftis Ql |
|
|
|
N |
|
Arbitrary; Chr 12p tetrasomy; Chromosom; Chromosomes; Fixed tissue; Ftis; Isochromosome 12p; Killian Syndrome; Killian/Teschler-Nicola Syndrome; Molecular genetics; Molecular pathology; MOLPATH; Ordinal; Pallister Killian Mosaic Syndrome; Pallister Mosaic Syndrome; PCR; Point in time; QL; Qual; Qualitative; Random; Screen; Teschler-Nicola/Killian Syndrome; Tissue; Tissue, unspecified |
2.66 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42636-1 |
Urease^3H post incubation |
PrThr |
Tiss |
Pt |
Ord |
|
|
ACTIVE |
Urease [Presence] in Tissue --3 hours post incubation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42636-1 |
|
|
|
|
Observation |
|
|
|
0 |
Urease 3h p Inc Tiss Ql |
|
|
|
N |
|
3h p Inc; After; CLO test; Clotest; Gastro; Gastroenterology; GI; Helicobacter pylori biopsy test; Microbiology; Ordinal; Point in time; PR; PST; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42637-9 |
Natriuretic peptide.B |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Natriuretic peptide B [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
Ref range 0 -100 |
|
|
|
|
|
CHEM |
|
42637-9 |
|
|
|
|
Both |
|
|
|
0 |
BNP Bld-mCnc |
|
|
|
N |
|
Beta Natriuretic Peptide; Blood; BNP; Brain Natriuretic Peptide; B-type natriuretic peptide; Cardio; Cardiology; Chemistry; Heart Disease; Level; Mass concentration; Natriutietic peptide.B; Pept; Point in time; QNT; Quan; Quant; Quantitative; Random; UniversalLabOrders; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
271 |
| 42638-7 |
Coagulation tissue factor induced |
Time |
PPP |
Pt |
Qn |
Coag.saline 1:1 |
|
ACTIVE |
Prothrombin time (PT) in Platelet poor plasma by Coagulation 1:1 saline |
|
MIN |
DefinitionDescription |
|
|
s |
Reference range 13-50 |
|
|
|
|
|
COAG |
|
42638-7 |
|
Coag.saline 1:1 |
|
|
Observation |
|
|
|
0 |
PT PPP 1:1 saline |
|
|
|
N |
|
1:1 saline; Clot; Clottable; Coag; Coagulation assay; Fac; Fact; Hematology; Heme; i; Plas; Platelet poor plasma; Point in time; Pro time; Prothrombin time; Protime; PT; QNT; Quan; Quant; Quantitative; Random; Tilt tube |
2.7 |
2.16 |
|
|
|
|
|
|
|
s |
|
|
|
0 |
| 42639-5 |
Immune complex.IgG |
ACnc |
Ser/Plas |
Pt |
Qn |
C1q binding assay |
|
ACTIVE |
Immune complex.IgG [Units/volume] in Serum or Plasma by C1q binding assay |
|
MIN |
DefinitionDescription |
|
|
ug Eq/mL |
|
|
|
|
|
|
SERO |
|
42639-5 |
|
C1q binding assay |
|
|
Both |
|
|
|
0 |
IC IgG SerPl C1Q Bind-aCnc |
|
|
|
N |
|
Arbitrary concentration; Bind; CIC; Circulating immune complex; Compx; IC; IC IgG; Imm; Immune globulin G; Immunoglobulin G; Imun; Imune; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 4264-8 |
Flurazepam |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Flurazepam [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4264-8 |
|
|
|
|
Observation |
|
|
|
0 |
Flurazepam Dose |
|
|
|
Y |
|
Dalmane; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 42640-3 |
Urease^1D post incubation |
PrThr |
Tiss |
Pt |
Ord |
|
|
ACTIVE |
Urease [Presence] in Tissue --1 day post incubation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42640-3 |
|
|
|
|
Observation |
|
|
|
0 |
Urease 1d p Inc Tiss Ql |
|
|
|
N |
|
1d p Inc; After; CLO test; Clotest; Gastro; Gastroenterology; GI; Helicobacter pylori biopsy test; Microbiology; Ordinal; Point in time; PR; PST; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 42641-1 |
Babesia sp DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Babesia sp DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Pos, Neg |
|
|
|
|
|
MICRO |
|
42641-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Babesia DNA Spec Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Babesiosis; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Piroplasmosis; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; species; spp; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; Updated Answer list type from NORMATIVE to EXAMPLE because the Answers in the list (Positive, Negative) are only examples of possible answers and not an exclusive list |
0 |
| 42642-9 |
Amikacin 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Method for Slow-growing mycobacteria |
|
ACTIVE |
Amikacin 2 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42642-9 |
|
Method for Slow-growing mycobacteria |
|
|
Observation |
|
|
|
0 |
Amikacin 2 ug/mL Islt SlowMyco |
|
|
|
N |
|
2 ug/mL; AFB; Amikin; Aminoglycosides; ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myco; Mycobacteria susceptibility; Mycobacterial susceptibility; Point in time; Random; SlowMyco; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; TB; Tuberculosis |
2.26 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 42643-7 |
Capreomycin 10.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Capreomycin 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42643-7 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Capreomycin 10 ug/mL Islt Slo |
|
|
|
N |
|
10 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; CAPASTAT; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Ogostal; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 42644-5 |
Ciprofloxacin 2.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ciprofloxacin 2.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42644-5 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ciprofloxacin 2 ug/mL Islt Sl |
|
|
|
N |
|
2 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; c250; c307; C81; Ciloxan; Cipro; Ciprofloxacn; Ciprofloxin; ID; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 42645-2 |
Ethambutol 10.0 ug/mL |
Susc |
Isolate |
Pt |
OrdQn |
Slow-growing Mycobacteria |
|
DEPRECATED |
Deprecated Ethambutol 10.0 ug/mL [Susceptibility] by Method for Slow-growing mycobacteria |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42645-2 |
|
Slow-growing Mycobacteria |
|
|
Observation |
|
|
|
0 |
Deprecated Ethambutol 10 ug/mL Islt Slow |
|
|
|
N |
|
10 ug/mL; ANTIBIOTIC SUSCEPTIBILITIES; AST; Etambol; Ethamb; ID; Inagen; Infectious Disease; InfectiousDisease; Islt; Isol; mcg; Myambutol; Mycobutol; Olbutam; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.36 |
2.16 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
